AOD-9604 vs Semaglutide: What Published Human Research Reports

TL;DR

- Semaglutide has large, published human evidence: in STEP 1, participants lost a mean of about 14.9 percent of body weight (roughly 15.3 kg) and 50.5 percent reached at least 15 percent body-weight loss (Wilding et al., 2021). - AOD-9604, a fragment of human growth hormone (residues 176 to 191), has limited human data; its 24-week Phase 2b obesity trial did not produce statistically significant weight loss versus placebo, the program was discontinued in 2007, and it holds no drug approval as a weight agent (Wilding, 2004). - The two work through different pathways: semaglutide is a GLP-1 receptor agonist that acts on appetite and satiety signaling, while AOD-9604 was studied for a proposed lipolytic (fat-releasing) effect supported mainly by preclinical work (Heffernan et al., 2001). - Semaglutide's reported side effects are mostly gastrointestinal (nausea, diarrhea), well documented across the STEP program (Wilding et al., 2021). - This page compares reported evidence only. It is not dosing guidance. Any personal decision belongs with a qualified clinician.

What is the core difference between AOD-9604 and semaglutide?

The core difference is evidence weight: semaglutide is a GLP-1 receptor agonist with large published human trials, while AOD-9604 is a growth-hormone fragment whose largest human trial did not beat placebo and whose development was halted in 2007.

Semaglutide belongs to the GLP-1 class, the same receptor family behind the largest modern weight-research results (Wilding et al., 2021). AOD-9604 is a short peptide copied from the tail end of the human growth hormone molecule, studied for a proposed fat-metabolism effect (Wilding, 2004). One has a deep clinical file. The other does not.

How do their mechanisms compare?

Semaglutide acts on GLP-1 receptors tied to appetite and satiety; AOD-9604 was studied for a proposed direct effect on fat breakdown, which human trials did not confirm.

GLP-1 receptor agonism slows gastric emptying and reduces hunger signaling, and this pathway produced the large weight changes seen in STEP 1 (Wilding et al., 2021) and, for the related agent tirzepatide, in SURMOUNT-1 (Jastreboff et al., 2022). AOD-9604 was designed to mimic the lipolytic region of growth hormone without the growth-promoting or glucose-raising effects of full growth hormone; this lipolytic action was reported in obese mouse models (Heffernan et al., 2001). That mechanism is plausible in animals, but the human results were modest and the program did not advance.

What does the human evidence actually show?

Semaglutide has multiple large randomized trials; AOD-9604 has only early-phase human work, and its pivotal Phase 2b trial did not separate from placebo, so the program was discontinued with no peer-reviewed pivotal publication.

For semaglutide, STEP 1 randomized adults with overweight or obesity and reported a mean change in body weight of about 14.9 percent (roughly 15.3 kg), with 50.5 percent of participants reaching at least 15 percent loss (Wilding et al., 2021). Regain after stopping is also documented: weight partly returned once treatment ended (Wilding et al., 2022), a pattern echoed in the withdrawal design of SURMOUNT-4 with tirzepatide (Aronne et al., 2024).

For AOD-9604, human evidence is limited. An early clinical profile described only modest effects in short Phase 2a testing (Wilding, 2004). The larger 24-week Phase 2b obesity study run by the developer, Metabolic Pharmaceuticals, did not produce a statistically significant weight reduction versus placebo, and the company reported discontinuation of the obesity program in 2007 (Wilding, 2004; developer trial reports, 2007). No completed peer-reviewed pivotal trial supports a weight-loss claim, and AOD-9604 has never received drug approval as a weight-loss agent; in the United States it was later placed on, and then removed from, the FDA interim 503A bulks list, and no FDA drug label exists (US FDA 503A bulks-list actions, 2024). These points should be read as a program that did not meet its efficacy bar, not as confirmed efficacy.

Comparison grid

What are the reported side effects of each?

Semaglutide's most reported effects are gastrointestinal, while AOD-9604's human safety profile is not well characterized because its trials were small and its pivotal study did not advance.

In STEP 1, nausea and diarrhea were the most common adverse events on semaglutide, and most were mild to moderate (Wilding et al., 2021). Because AOD-9604 did not complete large trials, there is no comparable published safety dataset. Absence of documented harm is not the same as proven safety; it reflects a lack of study.

What dose ranges did the research report?

In STEP 1, participants received semaglutide titrated to 2.4 mg once weekly (Wilding et al., 2021); AOD-9604 has no established, published human dose because its program was discontinued.

These figures describe what a named trial reported, not a recommendation. This page does not tell you what to take, how much, or how often. A qualified clinician is the correct route for any personal decision.

Which has stronger evidence for weight research?

Semaglutide has far stronger evidence, backed by large randomized trials, while AOD-9604 remains a limited-data compound whose pivotal trial did not beat placebo.

If the question is what published human research supports, semaglutide is the clear answer on evidence depth (Wilding et al., 2021). AOD-9604 may interest researchers studying growth-hormone fragments, but its human file is thin, its 24-week Phase 2b trial did not separate from placebo, and its development for weight loss did not continue past 2007 (Wilding, 2004). Realistic expectations matter here: the two are not on the same evidence footing.